AI-Native Scoping Reviews & Evidence Mapping

This review turns 1,815 original studies and 919,224 participants into a structured evidence map showing when barefoot walking/running may improve mechanics, balance, foot strength, or knee loading — and when it becomes clinically risky. It is especially useful for clinicians, runners, coaches, and researchers who need a clear, citation-linked map of barefoot biomechanics, diabetic-foot risk, falls, infection exposure, and safe transition strategies.

The main message of this paper is that current treatment of atherosclerosis relies mainly on standard preventive therapies—cholesterol lowering, combination lipid therapy, and blood-pressure control—whereas future treatment may come from more precise targeting of inflammation, endothelial injury, oxidative stress, immune pathways, and plaque biology. The review maps 47 original research topics, from combination therapies to cannabinoid receptor modulation, and 10 recurrent directions in the non-original literature, from lipid reduction to personalized imaging of plaque burden.

This review shows that atherosclerosis is not merely a late-life clinical disease, but a widespread silent substrate detectable across middle age, inflammatory disease, metabolic risk, genetic susceptibility, and even apparently low-risk populations. The full paper is worth reading because it maps where conventional risk scores may underestimate real vascular burden—and where selective imaging could redefine prevention.

This paper shows that asymptomatic carotid stenosis is no longer a simple “operate-or-observe” problem: under modern medical therapy stroke risk is often lower than once feared, yet a biologically high-risk subgroup still emerges through plaque vulnerability, hemodynamic failure, microemboli, and covert brain injury. The full review is worth reading because it maps where intervention may still matter, where overtreatment is likely, and how the field is shifting from stenosis percentage alone toward truly individualized risk stratification.

This review shows where clopidogrel truly outperforms aspirin, where the advantage disappears, and why the answer changes across PCI, stroke, PAD, gastrointestinal risk, and surgery. It turns a common everyday antiplatelet choice into a clinically practical evidence map of who may benefit more from clopidogrel, when aspirin may still be safer, and where the real uncertainties remain.

This review shows that aortic dissection treatment is no longer a simple “Type A surgery, Type B medicine” paradigm: outcomes now depend on timing, anatomy, malperfusion, remodeling strategy, and lifelong surveillance. The full paper is worth reading because it maps where TEVAR, open surgery, hybrid repair, medical stabilization, and emerging pharmacological strategies truly change survival—and where uncertainty still demands careful patient selection.

Aortic dissection is not predicted by diameter alone: hypertension, genetics, aortic geometry, pregnancy, medications, sleep apnea, inflammation, and environmental triggers all reshape individual risk. The full paper is worth reading because it maps where classic thresholds fail — and where modern risk stratification may prevent missed catastrophic events.

Aortic dissection prognosis is not determined by anatomy alone: early malperfusion, shock, inflammatory activation, renal injury, and false-lumen remodeling sharply define survival risk. This review maps 173 references to show which clinical, biomarker, genetic, and imaging signals can guide urgent triage, TEVAR/open-surgery strategy, and long-term surveillance intensity.

Aortic dissection prevalence is not one number — it changes dramatically by clinical setting, genetics, anatomy, sleep apnea, mental health burden, and referral selection. This review is worth reading because it maps where “rare disease” thinking fails and where targeted screening may reveal preventable high-risk phenotypes.

This review shows that aortic dissection diagnosis is no longer just “CTA or miss it” — the strongest modern pathway combines ADD-RS, D-dimer, ECG-gated CTA, bedside ultrasound, and selective AI/biomarker triage. The full paper is worth reading because it maps exactly where diagnosis still fails — atypical symptoms, stroke-like presentations, intramural hematoma, transfer misinterpretation — and which tools can realistically close those gaps.

Angioscopy emerges as the vascular “direct vision” tool that reveals what angiography often misses: thrombus, plaque rupture, yellow vulnerable plaques, incomplete stent healing, and embolic aortic sources. The full review is worth reading because it maps where this old but powerful technology still has modern clinical value — from coronary risk prediction and DES healing to carotid surgery, bypass quality control, flow-diverter follow-up, and cryptogenic stroke work-up.

AAA risk is not just “age and diameter”: this review shows smoking as the dominant driver, diabetes as a paradoxically protective signal, and women as lower-prevalence but higher-risk patients once aneurysm develops. The full evidence map explains which biological, anatomical, genetic, and post-EVAR surveillance signals may move AAA risk assessment beyond diameter alone.